TP53 and ovarian carcinoma: To confirm that sensitivity to gold(III) complexes was not dependent on p53 status, we utilized WT-p53 A2780 ovarian cancer cells in which p53 was knocked out using the CRISPR/Cas9 technology (CRISPR p53 KO).